11:02 AM EDT, 07/22/2024 (MT Newswires) -- Aligos Therapeutics ( ALGS ) said Monday it has entered into a clinical trial collaboration agreement with Xiamen Amoytop Biotech to finance and initiate a phase 1b exploratory clinical trial in China.

The trial will evaluate the safety and efficacy of ALG-000184, an oral small molecule capsid assembly modulator, in combination with Pegbing in chronic hepatitis B patients, the biopharmaceutical company added.

Pegbing is developed by Amoytop and is the 40kD pegylated interferon a-2b injection.

Aligos said it intends to start the trial after the National Medical Products Administration's approval in China.

Financial terms of the partnership weren't disclosed.

Shares of the company were up more than 7% in recent Monday trading.

Price: 0.54, Change: +0.04, Percent Change: +7.01